Ignite Creation Date:
2025-12-24 @ 11:53 AM
Ignite Modification Date:
2026-01-01 @ 5:40 AM
Study NCT ID:
NCT00059761
Status:
COMPLETED
Last Update Posted:
2015-11-17
First Post:
2003-05-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D002945', 'term': 'Cisplatin'}, {'id': 'D000077146', 'term': 'Irinotecan'}, {'id': 'D011878', 'term': 'Radiotherapy'}], 'ancestors': [{'id': 'D017606', 'term': 'Chlorine Compounds'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017672', 'term': 'Nitrogen Compounds'}, {'id': 'D017671', 'term': 'Platinum Compounds'}, {'id': 'D002166', 'term': 'Camptothecin'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 36}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2003-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-11', 'completionDateStruct': {'date': '2013-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-11-14', 'studyFirstSubmitDate': '2003-05-06', 'studyFirstSubmitQcDate': '2003-05-06', 'lastUpdatePostDateStruct': {'date': '2015-11-17', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2003-05-07', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maximum tolerated dose of irinotecan in combination with cisplatin and thoracic radiotherapy (45 Gy BID or 70 Gy daily) by toxicity assessment (Common Toxicity Criteria version 3.0) during acute and late toxicity', 'timeFrame': 'From the start of treatment until 90 days'}], 'secondaryOutcomes': [{'measure': 'Rate of non-dose limiting toxicity', 'timeFrame': 'From start of treatment to the end of follow-up'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['limited stage small cell lung cancer'], 'conditions': ['Lung Cancer']}, 'referencesModule': {'references': [{'type': 'RESULT', 'citation': 'Langer CJ, Swann S, Werner-Wasik M, et al.: Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): early analysis of RTOG 0241. [Abstract] J Clin Oncol 24 (Suppl 18): A-7058, 378s, 2006.'}, {'type': 'RESULT', 'citation': 'Langer C, Swann S, Werner-Wasik M, et al.: Phase I study of combination irinotecan and cisplatin and either twice daily thoracic radiation (45Gy) or once daily thoracic radiotherapy (70Gy) in patients with limited small cell lung carcinoma (SCLC): early toxicity analysis of RTOG 0241. [Abstract] Lung Cancer 49 (Suppl 2): A-P-777, S323, 2005.'}]}, 'descriptionModule': {'briefSummary': 'RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.\n\nPURPOSE: Phase I trial to study the effect on the body when combining irinotecan and cisplatin with radiation therapy in treating patients who have limited-stage small cell lung cancer that could not be completely removed during surgery.', 'detailedDescription': 'OBJECTIVES:\n\n* Determine the maximum tolerated dose of irinotecan administered with cisplatin and thoracic radiotherapy (given at two different schedules) in patients with limited stage small cell lung cancer.\n* Determine the qualitative and quantitative toxicity and non-dose-limiting toxicity of these regimens in these patients.\n* Determine the reversibility of all toxic effects associated with these regimens in these patients.\n\nOUTLINE: This is a non-randomized, dose-escalation study of irinotecan. Patients are assigned to 1 of 2 radiotherapy (RT) treatment groups.\n\n* Radiotherapy:\n\n * Group I: Patients undergo thoracic RT twice daily, 5 days a week, for 3 weeks.\n * Group II: Patients undergo thoracic RT once daily, 5 days a week, for 7 weeks.\n* Concurrent chemotherapy: Patients receive irinotecan IV over 60-90 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for 1 course for group I and 2 courses for group II.\n* Post RT chemotherapy: Patients receive irinotecan and cisplatin as above for 3 courses for group I and 2 courses, beginning after RT is complete, for group II.\n\nSequential cohorts of 6 patients per group receive escalating doses of irinotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.\n\nPatients are followed every 3 months for 1 year and then 6 months for 4 years.\n\nPROJECTED ACCRUAL: A total of 12-36 patients (6-18 per group) will be accrued for this study within 18 months.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed small cell lung cancer by one of two methods:\n\n * Fine needle aspiration biopsy\n * Two positive sputa\n* Must have limited disease as defined by all of the following:\n\n * Stage I-IIIB\n * Confined to 1 hemithorax\n * No T4 tumor based on malignant pleural or pericardial effusion\n\n * Patients with pleural effusion too small to tap under CT guidance and not evident on chest x-ray are allowed\n * No N3 disease based on contralateral hilar or contralateral supraclavicular involvement\n* Measurable or evaluable disease\n\n * Tumor must be able to be encompassed by specified radiotherapy fields without unacceptable risk of serious pulmonary compromise\n* No complete tumor resection\n* No pericardial effusion (regardless of cytology)\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nPerformance status\n\n* Zubrod 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute granulocyte count at least 1,500/mm\\^3\n* Platelet count at least 120,000/mm\\^3\n\nHepatic\n\n* Bilirubin no greater than 1.5 mg/dL\n* No known Gilbert's disease\n\nRenal\n\n* Creatinine no greater than 1.5 mg/dL\n\nCardiovascular\n\n* No myocardial infarction within the past 6 months\n* No symptomatic heart disease\n\nPulmonary\n\n* Forced expiratory volume (FEV)\\_1 at least 1.0 L/sec\n* No uncontrolled bronchospasms\n* No uncompensated chronic obstructive pulmonary disease\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No pre-existing peripheral neuropathy grade 2 or greater\n* No other malignancy within the past 2 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the bladder or cervix\n* No other concurrent serious medical illness\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior biologic therapy\n\nChemotherapy\n\n* No prior chemotherapy\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* No prior radiotherapy\n* No concurrent intensity-modulated radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n\nOther\n\n* At least 7 days since prior enzyme-inducing anti-convulsant drugs (EIACDs) (e.g., phenytoin, carbamazepine, or phenobarbital) if used on a regular basis for more than 2 weeks\n\n * Less than 2 weeks of regular use of EIACDs does not require a 7-day wash-out period\n* At least 14 days since prior Hypericum perforatum (St. John's wort)\n* No concurrent EIACDs\n* No concurrent amifostine during chemoradiotherapy\n* Concurrent gabapentin or other non-EIACDs allowed"}, 'identificationModule': {'nctId': 'NCT00059761', 'briefTitle': 'Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer', 'organization': {'class': 'NETWORK', 'fullName': 'Radiation Therapy Oncology Group'}, 'officialTitle': 'Phase I Study of Irinotecan and Cisplatin in Combination With Twice Daily Thoracic Radiotherapy (45 Gy) or Once Daily Thoracic Radiotherapy (70 Gy) for Patients With Limited Stage Small Cell Lung Cancer', 'orgStudyIdInfo': {'id': 'RTOG-0241'}, 'secondaryIdInfos': [{'id': 'CDR0000269348'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Sequence A: Level 1', 'description': 'Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID', 'interventionNames': ['Drug: cisplatin', 'Drug: irinotecan hydrochloride', 'Radiation: radiation therapy']}, {'type': 'EXPERIMENTAL', 'label': 'Sequence B: Level 1', 'description': 'Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily', 'interventionNames': ['Drug: cisplatin', 'Drug: irinotecan hydrochloride', 'Radiation: radiation therapy']}, {'type': 'EXPERIMENTAL', 'label': 'Sequence A: Level 2', 'description': 'Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID', 'interventionNames': ['Drug: cisplatin', 'Drug: irinotecan hydrochloride', 'Radiation: radiation therapy']}, {'type': 'EXPERIMENTAL', 'label': 'Sequence B: Level 2', 'description': 'Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily', 'interventionNames': ['Drug: cisplatin', 'Drug: irinotecan hydrochloride', 'Radiation: radiation therapy']}, {'type': 'EXPERIMENTAL', 'label': 'Sequence A: Level 3', 'description': 'Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID', 'interventionNames': ['Drug: cisplatin', 'Drug: irinotecan hydrochloride', 'Radiation: radiation therapy']}, {'type': 'EXPERIMENTAL', 'label': 'Sequence B: Level 3', 'description': 'Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily', 'interventionNames': ['Drug: cisplatin', 'Drug: irinotecan hydrochloride', 'Radiation: radiation therapy']}], 'interventions': [{'name': 'cisplatin', 'type': 'DRUG', 'armGroupLabels': ['Sequence A: Level 1', 'Sequence A: Level 2', 'Sequence A: Level 3', 'Sequence B: Level 1', 'Sequence B: Level 2', 'Sequence B: Level 3']}, {'name': 'irinotecan hydrochloride', 'type': 'DRUG', 'armGroupLabels': ['Sequence A: Level 1', 'Sequence A: Level 2', 'Sequence A: Level 3', 'Sequence B: Level 1', 'Sequence B: Level 2', 'Sequence B: Level 3']}, {'name': 'radiation therapy', 'type': 'RADIATION', 'armGroupLabels': ['Sequence A: Level 1', 'Sequence A: Level 2', 'Sequence A: Level 3', 'Sequence B: Level 1', 'Sequence B: Level 2', 'Sequence B: Level 3']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35294', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Comprehensive Cancer Center at University of Alabama at Birmingham', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '91505', 'city': 'Burbank', 'state': 'California', 'country': 'United States', 'facility': 'Providence Saint Joseph Medical Center - Burbank', 'geoPoint': {'lat': 34.18084, 'lon': -118.30897}}, {'zip': '94545', 'city': 'Hayward', 'state': 'California', 'country': 'United States', 'facility': 'Saint Rose Hospital', 'geoPoint': {'lat': 37.66882, 'lon': -122.0808}}, {'zip': '94550', 'city': 'Livermore', 'state': 'California', 'country': 'United States', 'facility': 'Valley Memorial Hospital', 'geoPoint': {'lat': 37.68187, 'lon': -121.76801}}, {'zip': '94602', 'city': 'Oakland', 'state': 'California', 'country': 'United States', 'facility': "Highland General Hospital at St. George's University School of Medicine", 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}}, {'zip': '94609', 'city': 'Oakland', 'state': 'California', 'country': 'United States', 'facility': 'CCOP - Bay Area Tumor Institute', 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}}, {'zip': '94609', 'city': 'Oakland', 'state': 'California', 'country': 'United States', 'facility': 'Summit Medical Center', 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}}, {'zip': '94806', 'city': 'San Pablo', 'state': 'California', 'country': 'United States', 'facility': 'J.C. Robinson, M.D. Regional Cancer Center', 'geoPoint': {'lat': 37.96215, 'lon': -122.34553}}, {'zip': '19718', 'city': 'Newark', 'state': 'Delaware', 'country': 'United States', 'facility': 'CCOP - Christiana Care Health Services', 'geoPoint': {'lat': 39.68372, 'lon': -75.74966}}, {'zip': '33308', 'city': 'Fort Lauderdale', 'state': 'Florida', 'country': 'United States', 'facility': 'Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'zip': '32610', 'city': 'Gainesville', 'state': 'Florida', 'country': 'United States', 'facility': 'University of Florida Shands Cancer Center', 'geoPoint': {'lat': 29.65163, 'lon': -82.32483}}, {'zip': '33021', 'city': 'Hollywood', 'state': 'Florida', 'country': 'United States', 'facility': 'Memorial Cancer Institute at Memorial Regional Hospital', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'zip': '33458', 'city': 'Jupiter', 'state': 'Florida', 'country': 'United States', 'facility': 'Ella Milbank Foshay Cancer Center at Jupiter Medical Center', 'geoPoint': {'lat': 26.93422, 'lon': -80.09421}}, {'zip': '33176', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Baptist-South Miami Regional Cancer Program', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33140', 'city': 'Miami Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'CCOP - Mount Sinai Medical Center', 'geoPoint': {'lat': 25.79065, 'lon': -80.13005}}, {'zip': '60637-1470', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'University of Chicago Cancer Research Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '52001', 'city': 'Dubuque', 'state': 'Iowa', 'country': 'United States', 'facility': 'Wendt Regional Cancer Center at Finley Hospital', 'geoPoint': {'lat': 42.50056, 'lon': -90.66457}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital Cancer Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48073', 'city': 'Royal Oak', 'state': 'Michigan', 'country': 'United States', 'facility': 'William Beaumont Hospital - Royal Oak Campus', 'geoPoint': {'lat': 42.48948, 'lon': -83.14465}}, {'zip': '65203', 'city': 'Columbia', 'state': 'Missouri', 'country': 'United States', 'facility': 'Ellis Fischel Cancer Center at University of Missouri - Columbia', 'geoPoint': {'lat': 38.95171, 'lon': -92.33407}}, {'zip': '07740', 'city': 'Long Branch', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Monmouth Medical Center', 'geoPoint': {'lat': 40.30428, 'lon': -73.99236}}, {'zip': '08060', 'city': 'Mount Holly', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Fox Chase Virtua Health Cancer Program - Marlton', 'geoPoint': {'lat': 39.99289, 'lon': -74.78766}}, {'zip': '08240', 'city': 'Pomona', 'state': 'New Jersey', 'country': 'United States', 'facility': 'AtlantiCare Regional Medical Center', 'geoPoint': {'lat': 39.47845, 'lon': -74.57516}}, {'zip': '10940', 'city': 'Middletown', 'state': 'New York', 'country': 'United States', 'facility': 'Tucker Center for Cancer Care at Orange Regional Medical Center', 'geoPoint': {'lat': 41.44593, 'lon': -74.42293}}, {'zip': '13210', 'city': 'Syracuse', 'state': 'New York', 'country': 'United States', 'facility': 'SUNY Upstate Medical University Hospital', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'zip': '27599', 'city': 'Chapel Hill', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill', 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Duke Comprehensive Cancer Center', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '27534', 'city': 'Goldsboro', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wayne Memorial Hospital, Incorporated', 'geoPoint': {'lat': 35.38488, 'lon': -77.99277}}, {'zip': '27534', 'city': 'Goldsboro', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wayne Radiation Oncology', 'geoPoint': {'lat': 35.38488, 'lon': -77.99277}}, {'zip': '27893', 'city': 'Wilson', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wilson Medical Center', 'geoPoint': {'lat': 35.72127, 'lon': -77.91554}}, {'zip': '44307', 'city': 'Akron', 'state': 'Ohio', 'country': 'United States', 'facility': 'McDowell Cancer Center at Akron General Medical Center', 'geoPoint': {'lat': 41.08144, 'lon': -81.51901}}, {'zip': '19026', 'city': 'Drexel Hill', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Delaware County Regional Cancer Center at Delaware County Memorial Hospital', 'geoPoint': {'lat': 39.94706, 'lon': -75.29213}}, {'zip': '17033-0850', 'city': 'Hershey', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Penn State Cancer Institute at Milton S. Hershey Medical Center', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '19107', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Kimmel Cancer Center at Thomas Jefferson University - Philadelphia', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '19141', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Albert Einstein Cancer Center', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15219', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Mercy Cancer Institute at Mercy Hospital', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '29601', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Bon Secours St. Francis Health System', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '29605', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Greenville Hospital System Cancer Center', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '29615', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'CCOP - Greenville', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '37404', 'city': 'Chattanooga', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Sarah Cannon Cancer Center at Parkridge Medical Center', 'geoPoint': {'lat': 35.04563, 'lon': -85.30968}}, {'zip': '37232', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Vanderbilt-Ingram Cancer Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'M.D. Anderson Cancer Center at University of Texas', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '84107', 'city': 'Murray', 'state': 'Utah', 'country': 'United States', 'facility': 'Cottonwood Hospital Medical Center', 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'zip': '84403', 'city': 'Ogden', 'state': 'Utah', 'country': 'United States', 'facility': 'McKay-Dee Hospital Center', 'geoPoint': {'lat': 41.223, 'lon': -111.97383}}, {'zip': '84603', 'city': 'Provo', 'state': 'Utah', 'country': 'United States', 'facility': 'Utah Valley Regional Medical Center - Provo', 'geoPoint': {'lat': 40.23384, 'lon': -111.65853}}, {'zip': '84106', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'Utah Cancer Specialists at UCS Cancer Center', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '84143', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'LDS Hospital', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '84770', 'city': 'St. George', 'state': 'Utah', 'country': 'United States', 'facility': 'Dixie Regional Medical Center', 'geoPoint': {'lat': 37.10415, 'lon': -113.58412}}, {'zip': '54601', 'city': 'La Crosse', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center', 'geoPoint': {'lat': 43.80136, 'lon': -91.23958}}], 'overallOfficials': [{'name': 'Corey J. Langer, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Fox Chase Cancer Center'}, {'name': 'Maria Werner-Wasik, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Sidney Kimmel Cancer Center at Thomas Jefferson University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Radiation Therapy Oncology Group', 'class': 'NETWORK'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}